Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 6
2006 3
2007 7
2008 4
2009 5
2010 4
2011 2
2012 7
2013 7
2014 3
2015 9
2016 8
2017 7
2018 6
2019 5
2020 6
2021 6
2022 3
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma.
Strecker MI, Wlotzka K, Strassheimer F, Roller B, Ludmirski G, König S, Röder J, Opitz C, Alekseeva T, Reul J, Sevenich L, Tonn T, Wels WS, Steinbach JP, Buchholz CJ, Burger MC. Strecker MI, et al. Among authors: wels ws. Oncoimmunology. 2022 Oct 11;11(1):2127508. doi: 10.1080/2162402X.2022.2127508. eCollection 2022. Oncoimmunology. 2022. PMID: 36249274 Free PMC article.
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Hegde M, et al. Among authors: wels ws. J Clin Invest. 2016 Aug 1;126(8):3036-52. doi: 10.1172/JCI83416. Epub 2016 Jul 18. J Clin Invest. 2016. PMID: 27427982 Free PMC article.
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.
Burger MC, Forster MT, Romanski A, Straßheimer F, Macas J, Zeiner PS, Steidl E, Herkt S, Weber KJ, Schupp J, Lun JH, Strecker MI, Wlotzka K, Cakmak P, Opitz C, George R, Mildenberger IC, Nowakowska P, Zhang C, Röder J, Müller E, Ihrig K, Langen KJ, Rieger MA, Herrmann E, Bonig H, Harter PN, Reiss Y, Hattingen E, Rödel F, Plate KH, Tonn T, Senft C, Steinbach JP, Wels WS. Burger MC, et al. Among authors: wels ws. Neuro Oncol. 2023 Nov 2;25(11):2058-2071. doi: 10.1093/neuonc/noad087. Neuro Oncol. 2023. PMID: 37148198 Free PMC article.
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.
Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. Ahmed N, et al. Among authors: wels ws. JAMA Oncol. 2017 Aug 1;3(8):1094-1101. doi: 10.1001/jamaoncol.2017.0184. JAMA Oncol. 2017. PMID: 28426845 Free PMC article. Clinical Trial.
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S. Ahmed N, et al. Among authors: wels ws. J Clin Oncol. 2015 May 20;33(15):1688-96. doi: 10.1200/JCO.2014.58.0225. Epub 2015 Mar 23. J Clin Oncol. 2015. PMID: 25800760 Free PMC article. Clinical Trial.
ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Heim C, Moser LM, Kreyenberg H, Bonig HB, Tonn T, Wels WS, Gradhand E, Ullrich E, Meister MT, Koerkamp MG, Holstege FCP, Drost J, Klusmann JH, Bader P, Merker M, Rettinger E. Heim C, et al. Among authors: wels ws. Front Immunol. 2023 Aug 18;14:1228894. doi: 10.3389/fimmu.2023.1228894. eCollection 2023. Front Immunol. 2023. PMID: 37662907 Free PMC article.
Advantages and applications of CAR-expressing natural killer cells.
Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, Grez M, Kloess S, Arseniev L, Koehl U. Glienke W, et al. Among authors: wels ws. Front Pharmacol. 2015 Feb 12;6:21. doi: 10.3389/fphar.2015.00021. eCollection 2015. Front Pharmacol. 2015. PMID: 25729364 Free PMC article. Review.
93 results